Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy
Year: 2022
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Andrew J Davies, Louise Stanton, Josh Caddy, Sharon Barrans, Sam Wilding, Geoff N Saunders, Christoph Mamot, Urban Novak, Andrew K. McMillan, Paul A Fields, Graham P. Collins, Richard Stephens, Francesco Cucco, Chulin Sha, Moniek Van Hoppe, Reuben M Tooze, Matthew A Care, Gareth Griffiths, Anna Schuh, Ming-Qing Du, David R Westhead, Cathy Burton, Peter Johnson
Institutions: NIHR CRUK Experimental Cancer Medicine Centre, University of Southampton, Leeds Teaching Hospitals NHS Trust, Swiss Group For Clinical Cancer Research, Kantonsspital Aarau, University of Bern, University Hospital of Bern, Nottingham University Hospitals NHS Trust, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, Kings Health Partners, University of Oxford, Oxford University Hospitals NHS Trust, National Cancer Research Institute, University of Cambridge, Chinese Academy of Sciences, University of Leeds, Cancer Research UK
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310125515